TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Spinal Mobility Reeducation in Patients Treated for a Lumbar Spinal Stenosis After Epidural Infiltration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \> 50 years,~* central, acquired and multi-staged lumbar spinal stenosis,~* pain since at least three months,~* radicular pains higher than the lumbar pains,~* walking distance \< 1000 m,~* oral consent.~Exclusion Criteria:~* intercurrent pathology limiting the walking distance (arteriopathy, cardio-respiratory insufficiency, disabling arthrosis affecting the lower limbs...),~* history of spinal surgery for lumbar spinal stenosis,~* extended lumbar arthrodesis (equal to or greater than 2 levels),~* monosegmental and degenerative spondylolisthesis,~* foraminal stenosis,~* motor deficit of the lower limbs or Cauda equina syndrome (Cauda equina syndrome (CES) is a serious neurologic condition in which damage to the cauda equina causes acute loss of function of the lumbar plexus, (nerve roots) of the spinal canal below the termination (conus medullaris) of the spinal cord),~* bleeding disorders or allergies contraindicating the epidural infiltration.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (C) (Type: ACTIVE_COMPARATOR): Kyphosis reeducation + patient education + auto-reeducation at home
- Test group (M) (Type: OTHER): Spinal mobility reeducation + patient education + auto-reeducation at home.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be able to review and sign informed consent.~* Subjects must require biliary stenting for the relief of their symptoms as well as FNA biopsy for proper diagnosis.~* Suspected mass should be located in the head, uncinate, or neck of the pancreas.~Exclusion Criteria:~* Cannot give and sign informed consent.~* The suspected mass is located in the body or tail of the pancreas.~* The patient may be a candidate for palliative biliary stenting (in which a metal stent would be placed)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EUS-FNA First (Type: ACTIVE_COMPARATOR): Patients will undergo EUS-FNA first, followed by ERCP with biliary stenting (using a plastic stent).
- ERCP with stent placement first (Type: ACTIVE_COMPARATOR): Patients will undergo ERCP with stent placement first, followed by EUS-FNA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Education by Telemedicine in Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 65 years old hospitalized for acute heart failure~* Left ventricle systolic Dysfunction with ejection fraction \< 45 %, documented in the previous 6 months~* And at least one of the following criteria:~BNP before discharge from hospital \> 350 pg/ml / EF \< 35 % / Hospitalization for acute heart failure informed in the previous 6 months~Exclusion Criteria:~* NYHA 4 at hospital discharge~* Planned cardiac surgery or coronary revascularization~* Hospitalization for ST-elevation acute coronary syndrome~* Depressive syndrome with score \> 20 at geriatric depression scale~* Therapeutic education impossible~* Technical problems with the device~* Limited autonomy for device use~* Patient not living in Basse-Normandie~* Ongoing participation in another clinical trial

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Optimal medical treatment of Heart failure and therapeutic education
- Telemedicine (Type: EXPERIMENTAL): Optimal medical treatment of heart failure disease and therapeutic education

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients 18 years of age or older.~* Patients must sign an informed consent.~* Patients should be in such a health condition in the opinion of the attending physician that with the administration of mifepristone benefits may outweigh risks.~Exclusion Criteria:~* Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): 200 mg RU-486 (Mifepristone) daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe preeclampsia at less than 26 weeks' gestation~* Singleton pregnancy~* Signed consent~Exclusion Criteria:~* Multiple pregnancy~* Gestational age at 26 or above weeks' gestation~* Estimated foetal weight at diagnosis \<5th percentile~* Abnormal fetal heart rate at entry, where feasible (\>24 weeks' gestation)~* Maternal complications at diagnosis: Uncontrolled blood pressure, HELLP syndrome, abruption, eclampsia pulmonary edema, renal failure, liver hematoma

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Apheresis arm (Type: EXPERIMENTAL): Apheresis for extracorporal removal of sFlt-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable Alzheimer disease~* Completed preceding double-blind study (3133L1-2203 US)~* MMSE score \> 9.~Exclusion Criteria:~* Significant brain MRI abnormalities~* Clinically important psychiatric symptoms~* History of stroke

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 5 mg/week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improving Medication Adherence in Post-ACS Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Medical eligibility:~   1. Patient presenting for staged intervention with positive cardiac history OR~  2. Patient with stable CAD who received cardiac admission but does not report chest pain. OR~  3. Patient with stable CAD who has had a cardiac admission in the past.~2. Patient is non-adherent to prescribed medication.~The following exclusion criteria have been set for either safety concerns or concerns that patients will not be able to complete the protocol:~1. inability to communicate in English or Spanish~2. unwilling to be randomized or to have aspirin in a separate bottle if they use a pill box~3. unavailability for the 1 month period of the study (including being unavailable by phone and/or traveling out of the country)~4. medically unable to receive aspirin (e.g. allergy, contra-indicated, etc)~5. deemed unable to comply with the protocol (either self selected or by indicating during screening that s/he could not complete all requested tasks). This includes patients with a level of cognitive impairment indicative of dementia, and patients with current alcohol or substance abuse.~6. deemed to need immediate psychiatric assessment (e.g., must be hospitalized, or have some other psychiatric intervention conducted within 72 hours).~7. active psychosis, bipolar disorder, or any overt personality disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: NO_INTERVENTION): Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians.
- B (Type: EXPERIMENTAL): Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Retinal Microvascularization and Cardiovascular Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Person who gave oral consent~* High cardiovascular risk group: Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)~* Low cardiovascular risk group: Adult patients over 40 years of age recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery, ocular surface pathologies and optical correction.~Exclusion Criteria:~* Person not affiliated to national health insurance~* Patient refusal~* Minor patient~* Protected patient~* Ophthalmological history (macular vascular or degenerative disorders)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High cardiovascular risk patients (Type: None): Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)
- Low cardiovascular risk patients (Type: None): Adult patients recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery.~The age balance of the patients included in the two groups will be checked regularly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Drug Coated Balloons vs Plain Balloons for the Management of Dysfunctional Dialysis Fistula

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria~  * \>18 year old~ * Dysfunctional dialysis fistula~* Radiocephalic~* Brachiocephalic~* Brachiobasilic~Clinical criteria for diagnosis of dysfunctional fistula:~* Swelling of the fistula limb~* Prolonged bleeding after withdrawing access needles~* Abnormal pulsations or weak thrill.~* Functional criteria for the diagnosis of dysfunctional criteria:~* Arteriovenous fistula is unable to deliver dialysis blood flow (Qb) of equal to or more than 300 ml/min and/or access recirculation of more than 10% on at least two occasions,~* A rising trend of venous pressure or excessive negative arterial pressure, and/or unable to deliver a Kt/v of 1.2 or more.~* Non-thrombosed~Exclusion Criteria:~* Dysfunctional arteriovenous (AV) grafts~* Thrombosed fistulas~* Intra-stent stenosis~* Stenoses not responding to balloon angioplasty and requiring stenting.~* Stenosis less than 50%~* Surgical intervention that excludes the treatment segment from the access circuit~* Systemic or local (to the fistula) infection treated for less than 10 days prior to the study procedure~* Location of isolated stenosis central to the thoracic inlet.~* Women who are breastfeeding, pregnant or are intending to become pregnant~* Known hypersensitivity or contraindication to contrast medium which cannot be adequately premeditated.~* Sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or paclitaxel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug coated balloon angioplasty (Type: EXPERIMENTAL): * Vessel preparation with Pre dilatation~* Vessel treatment with Drug-coated balloon
- Plain balloon angioplasty (Type: ACTIVE_COMPARATOR): * Vessel preparation with Pre dilatation~* Vessel treatment with additional Plain balloon angioplasty:

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New Prophylactic Maneuver: the Pushing Maneuver, Aiming to Reduce the Risk for Shoulder Dystocia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women having completed 37 or more gestational weeks with singleton vertex fetus, delivering vaginally~Exclusion Criteria:~* patients with caesarean section are excluded

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- group M (Type: OTHER): Normal delivery without pushing maneuver suctioning of fetal nose and mouth during delivery
- group C (Type: EXPERIMENTAL): Pushing maneuver on the fetal head

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women or men \> 60 years~* DXA T-Score at lumbar spine, total hip or femur neck \<-2,0 before the start of the bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral densitiy~* Pretreatment with bisphosphonates for at least four years~* Risk for hip and vertebral fractures min. 30% according to DVO-guideline for osteoporosis 2009~* Signed informed consent~Exclusion Criteria:~* Other pharmacological treatment of osteoporosis during the last 48 months~* Other bone diseases~* Malabsorption syndromes~* Renal insufficiency with a calculated creatinine clearance \< 35 ml/min~* Diseases of the esophagus, delayed esophageal clearance~* UUnability to realise the intake instructions~* Hypocalcemia

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alendronate (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clamping vs. Free Drainage Before the Removal of Short-term Indwelling Urethral Catheters in Internal Medicine Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients of both sexes, aged between 18 and 85 years who require IUC 18 short-term (1 to 14 days) in the units of internal medicine at University Hospital Alcorcón Foundation.~Patients who express a desire to participate in the study by signing the informed consent.~Exclusion Criteria:~* Patients with permanent long-term (15 days or more) urinary catheter. Patients with recurrent episodes of UTI, which has submitted episodes of urinary retention in the last month, or who have urologic pathology.~Patients with cognitive impairments that hinder communication with the medical staff.~Disoriented patients in person, time and place. Anatomical and physiological genito-urinary system Alterations Patients taking a drug that affects the bladder and kidney function the week prior to catheterization.~Pregnant patients. Patients with a known history of benign prostatic hyperplasia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Clamping group (Type: EXPERIMENTAL): Indwelling urinary catheter is clamped before removal and unclamped when the patient expresses his desire to urinate.
- Free drainage group (Type: NO_INTERVENTION): The urinary catheter will be removed without prior clamping.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Recreation Therapy Wellness Recovery Program for Individuals With Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Potential subjects in this study will have a diagnosis of Parkinson's disease.~* Potential subjects in this study are able to tolerate a 60-minute exercise program; participants complete the Parkinson Power Moves Class Application which requires a release form and a physician's signature that identifies any limitations or precautions to be taken in the program.~Exclusion Criteria:~* Individuals who do not have a diagnosis of Parkinson's disease or those with PD who are not medically cleared to participate in the program will be excluded.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Recreational Therapy Wellness Recovery Program Group (Type: EXPERIMENTAL): All participants will enter a baseline data collection period for two weeks. They will then participate in a 12-week community-based Recreational Therapy (RT) Wellness Recovery Program (WRP) for individuals with Parkinson's disease (WRP).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both sexes older than 18 years~* Patient diagnosed of CROHN´s disease~* Patient with intestinal stenosis length equal or less than 5cm previously confirmed with bowel magnetic resonance imaging (3 stenosis as maximum)~* Stenosis no permeable for endoscopy(12mm in case of accessible stenosis with conventional colonoscopy and 10mm in case of accessible stenosis with balloon enteroscopy)~* Dilated stenosis according to endoscopist criteria (pass or no the endoscopy)~* Patient capable of participate in the examinations required by the study~* Patient after being informed, give his/her informed consent in writing~Exclusion Criteria:~* Patients with large intestinal stenosis (more than 6cm) and multiples~* Patients with previous or actual treatment with anti-tumor necrosis factor (anti-TNF) drugs~* Patients with positive serology to hepatitis B virus(HBV),hepatitis C virus (HCV), or HIV~* Patients with positive screening to Tuberculosis(positive PPD)~* Established contraindication to anti-TNF drugs~* Existence of fistulous tracts associated with intestinal stenosis~* Neoplastic process associated with stenosis or in another location~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): single administration of Adalimumab 80mg diluted in 5ml saline
- saline (Type: PLACEBO_COMPARATOR): 5 ml of saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues